The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis

An edition of The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis (2002)

The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis

By Andreas Maetzel

0 (0 Ratings)

0 Want to read0 Currently reading0 Have read

Publish Date

2002

Publisher

Canadian Coordinating Office for Health Technology Assessment

Language

eng

Pages

Description:

subjects: Cost effectiveness, Therapeutic use, Osteoarthritis, Drug therapy, Chemotherapy, Cost-Benefit Analysis, Rheumatoid arthritis, Nonsteroidal anti-inflammatory agents, Cyclooxygenase 2, Rofecoxib, Cyclooxygenase Inhibitors, Arthritis, Rheumatoid, Inhibitors, Celecoxib